- Home
- LEGH vs CATX Comparison
LEGH vs CATX Comparison
Compare LEGH & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGH | CATX |
|---|---|---|
| Founded | 2005 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.2M | 609.4M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LEGH | CATX |
|---|---|---|
| Price | $19.35 | $5.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $25.00 | $11.89 |
| AVG Volume (30 Days) | 88.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.29 | ★ 29.31 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $184,191,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.07 | N/A |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.84 | $1.60 |
| 52 Week High | $29.45 | $6.16 |
Technical Indicators
Market Signals| Indicator | LEGH | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 54.10 |
| Support Level | $18.93 | $3.24 |
| Resistance Level | $22.69 | $5.39 |
| Average True Range (ATR) | 0.69 | 0.38 |
| MACD | -0.25 | -0.10 |
| Stochastic Oscillator | 16.67 | 29.20 |
Price Performance
Historical ComparisonAbout LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.